Andreas
1
All posts from Andreas
Andreas in Andrey,

Investment idea - REGN

Recently, the company Regeneron Pharmaceuticals (REGN) published the financial report for 2Q13, according to which the EPS of the company was better than analysts ' forecasts. So, EPS was $1.73  (consensus: $0,86), the total revenues was $457,6 million (consensus: $470,3 million). The company's portfolio includes several products: Eylea, Zaltrap, Arcalyst, Sarilumab, and REGN727. The share of Eylea amounts to 72% of total sales of the company. Sales of this drug coincided with the forecast. This year was the explosive growth of sales of this drug compared with last year. The management of the company expects 10-15% increase of sales of this drug in the following year. This preparation is intended for the treatment of wet form of age-related macular eye degeneration of older patients. Also the perspective drugs (which can become new best sellers of the company) are Sarilumab, and Alirocumab (REGN727), which are intended to reduce the level of cholesterol in the blood and are used to treat cardiovascular diseases. Trials of these drugs are scheduled for 2014. Our medium-term fundamental valuation of REGN shares is $327. Short-term goal is $288.